| Literature DB >> 19363468 |
L N Kaliberova1, V Krendelchtchikova, D K Harmon, C R Stockard, A S Petersen, J M Markert, G Y Gillespie, W E Grizzle, D J Buchsbaum, S A Kaliberov.
Abstract
Malignant forms of glioma, the most common primary brain tumors, remain poorly responsive to multimodality therapeutic interventions, including chemotherapy. Suppressed apoptosis and extraordinary invasiveness are important distinctive features that contribute to the malignant phenotype of glioma. We have developed the vascular endothelial growth factor receptor 1 (VEGFR-1/flt-1) conditional replicating adenoviral vector (CRAdRGDflt-IL24) encoding the interleukin-24 (IL-24) gene. We investigated whether a combination of CRAdRGDflt-IL24-mediated oncolytic virotherapy and chemotherapy using temozolomide (TMZ) produces increased cytotoxicity against human glioma cells in comparison with these agents alone. Combination of CRAdRGDflt-IL24 and TMZ significantly enhanced cytotoxicity in vitro, inhibited D54MG tumor growth and prolonged survival of mice harboring intracranial human glioma xenografts in comparison with CRAdRGDflt-IL24 or TMZ alone. These data indicate that combined treatment with CRAdRGDflt-IL24-mediated oncolytic virotherapy and TMZ chemotherapy provides a promising approach for glioma therapy.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19363468 PMCID： PMC4332514 DOI： 10.1038/cgt.2009.23
Source DB: PubMed Journal: Cancer Gene Ther ISSN： 0929-1903 Impact factor: 5.987